Carcinosarcoma

Observed

← altered in cohorts of

MELTF

46 / 57 cases (81 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PIK3CA

46 / 57 cases (81 %) · ssm · TCGA-UCS · largest of 4 cohorts

—

Observed

← altered in cohorts of

ADRM1

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

APOD

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ATP13A4

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ATP13A5

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

EEF1AKMT4-ECE2

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

FBXO45

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

FGF12

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

GATA5

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

LAMA5

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

MB21D2

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

MUC4

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

OPA1

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

OSTN

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PSMA7

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

RNF168

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

SENP5

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TRA2B

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

YEATS2

45 / 57 cases (79 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ACAP2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

AHSG

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ARFGEF2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ATP11B

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ATP13A3

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

CABLES2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

CEP19

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

COL20A1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

CPN2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

DGKG

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

DLG1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

DVL3

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ECE2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

FNDC11

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

GP5

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

HRH3

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

KLHL24

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

KNG1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

LRRC15

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

LSM14B

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

MAGEF1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

MCF2L2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

MTG2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

NCBP2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

NCBP2AS2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

NRROS

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

OSBPL2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

P3H2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PAK2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PCYT1A

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PIGX

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PIGZ

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PLAAT1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PPP1R2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PYDC2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

RBBP8NL

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

RPS21

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

SLC51A

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

SMCO1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

SS18L1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

STAU1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TCTEX1D2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TFRC

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TM4SF19

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TM4SF19-TCTEX1D2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TMEM41A

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TNK2

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

UBXN7

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

WDR53

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

XXYLT1

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ZDHHC19

44 / 57 cases (77 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ALG3

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

BCL6

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

CLDN1

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

EHHADH

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

EIF4G1

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

ETV5

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

FAM131A

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

HES1

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

HRG

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

HTR3C

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

HTR3D

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

HTR3E

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

KCNQ2

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

KLHL6

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

LAMP3

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

LIPH

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

MAP3K13

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

MCCC1

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PARL

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

PHC3

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

POLR2H

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

SKIL

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TBL1XR1

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TMEM207

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TMEM44

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

TPRG1

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

← altered in cohorts of

VWA5B2

43 / 57 cases (75 %) · ssm · TCGA-UCS

—

Observed

Uterine Malignant Mixed Mesodermal (Mullerian) Tumor

← altered in cohorts of

FBXW7

22 / 57 cases (39 %) · ssm · ucs_tcga · largest of 3 cohorts

—

Observed

cbioportal

Uterine Malignant Mixed Mesodermal (Mullerian) Tumor

← altered in cohorts of

FRG1BP

21 / 57 cases (37 %) · ssm · ucs_tcga

—

Observed

cbioportal

Carcinosarcoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 46show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 14 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 10 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall_molecule 10 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall_molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Aldesleukinother 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall_molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →

Carcinosarcoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 46show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

14 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

10 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall_molecule

10 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal_antibody

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall_molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal_antibody

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aldesleukinother

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cediranibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall_molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor

Carcinosarcoma studied in …STUDIED_INderived10 of 77show all (up to 200)
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 77 trials mapped (24 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03651206Phase 2/Phase 3 · recruiting Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Ovarian Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06568172Phase 3 · suspended Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer · condition mapped CURATED_BROADER · 77 trials mapped (24 active)	—	—	Skin Squamous Cell Carcinoma with Sarcomatoid Differentiation	1	Observed	clinicaltrials	graph →
→ studied in	NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · condition mapped PROBABILISTIC · 77 trials mapped (24 active)	—	—	Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07741968NA · recruiting A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Ovarian Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05646316Phase 3 · recruiting Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 77 trials mapped (24 active)	—	—	Uterine Corpus Carcinosarcoma	1	Observed	clinicaltrials	graph →

Carcinosarcoma studied in …STUDIED_INderived10 of 77show all (up to 200)

→ studied in

NCT05256225Phase 3 · recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT05920798Phase 1/Phase 2 · active not recruiting

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 77 trials mapped (24 active)

—

Observed

Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT02101775Phase 2 · active not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)

—

Observed

→ studied in

NCT03651206Phase 2/Phase 3 · recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)

—

Ovarian Carcinosarcoma

Observed

Skin Squamous Cell Carcinoma with Sarcomatoid Differentiation

→ studied in

NCT06568172Phase 3 · suspended

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer · condition mapped CURATED_BROADER · 77 trials mapped (24 active)

—

Observed

→ studied in

NCT03660826Phase 2 · active not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · condition mapped PROBABILISTIC · 77 trials mapped (24 active)

—

Observed

→ studied in

NCT07741968NA · recruiting

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)

—

Ovarian Carcinosarcoma

Observed

→ studied in

NCT05646316Phase 3 · recruiting

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT06580314Phase 3 · recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)

—

Observed

Uterine Corpus Carcinosarcoma

→ studied in

NCT03120624Phase 1 · active not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 77 trials mapped (24 active)

—

Observed